key: cord-0077445-hckbak5r
authors: Badawy, Mohamed A. S.; Abdelall, Eman K. A.; EL-Nahass, EL-Shaymaa; Abdellatif, Khaled R. A.; Abdel-Rahman, Hamdy M.
title: Design, synthesis, biological assessment and in silico ADME prediction of new 2-(4-(methylsulfonyl) phenyl) benzimidazoles as selective cyclooxygenase-2 inhibitors
date: 2021-08-17
journal: nan
DOI: 10.1039/d1ra04756f
sha: 79a5a6b8768fa9be405cb205d18c43f6296b4b07
doc_id: 77445
cord_uid: hckbak5r

A novel series of benzimidazole derivatives wherein 4-(methylsulfonyl) phenyl pharmacophore attached via its C-2 position was designed and synthesized. These compounds were evaluated in vitro as cyclooxygenase-1(COX-1)/cyclooxygenese-2(COX-2) inhibitors. Furthermore, the synthesized compounds were also in vivo evaluated for their anti-inflammatory activity and ulcerogenic liability. Examination of histopathological lesions was also performed to evaluate the cariogenic effect of most active compounds. In silico prediction of physicochemical properties, ADME, and drug-likeness profiles were also studied. Several compounds as 11b, 11k, 12b, and 12d showed selective inhibition to (COX-2) isozyme. Compound 11b showed the most potent (COX-2) inhibitory activity with (IC(50) = 0.10 μM) and selectivity index (SI = 134); the tested compounds also have shown good anti-inflammatory activity. Regarding the ulcerogenic liability, compound 11b was also safest one (Ulcer Index) (UI = 0.83). The results of the molecular docking studies is closely related to the results of the in vitro COX-2 inhibitory activities.

Non-steroidal anti-inammatory drugs (NSAIDs) are used to treat a wide range of inammatory diseases, such as pain, fever and arthritis. 1, 2 NSAIDs are still the rst choice for the management of such cases. 3 The inammatory process starts with the biotransformation of arachidonic acid (AA) in the cell membrane, and is then catalyzed by both cyclooxygenases (COXs) and lipoxygenase (LOX) enzyme families to produce prostaglandins (PGs) and leukotrienes (LTs), respectively. 4 NSAIDS are capable of reducing the production of key pro-inammatory mediator's prostaglandins (PGs) by the inhibition of constitutive (COX-1) and inducible (COX-2) isozymes. 5 However, certain side effects are associated with their long use including bleeding, hepatotoxicity, and cardiovascular disorders. The inhibition of constitutive COX-1 is responsible for these side effects because it is considered a housekeeping enzyme, which is responsible for maintaining the integrity of gastric, renal and platelet cell functions. 6 Non-selective NSAIDS usually inhibit both COX-1 and COX-2 and consequently might show all the above side effects. Indomethacin (1), as a potent non-selective NSAID, has substantial medical applications in the treatment of inammation diseases including osteoarthritis, rheumatoid, and ankylosing spondylitis. 7 Clinical trials have shown that selective COX-2 inhibitors as celecoxib have signicantly better safety proles. [8] [9] [10] According to structure-activity relationship (SAR) studies, selective COX-2 inhibitors are diaryl heterocyclic compounds bearing -SO 2 NH 2 , or -SO 2 CH 3 groups (Fig. 1) . The whole COX-2 inhibitor molecule is pushed by a sterically bulky group into the hydrophobic and large in volume COX-2 enzyme. [11] [12] [13] [14] Benzimidazole derivatives are of great medicinal importance due to their wide biological activities such as anti-inammatory, 15 anticancer, 16, 17 antimicrobial, 18-20 antiviral, 21 antihypertensive, 22 ,23 antifungal 24 and antibacterial activities. [25] [26] [27] Therefore, our strategy to modify indomethacin structure to get selective COX-2 inhibitor is summarized as follows, (i) Benzimidazole core instead of the indole core.

(ii) Five atom spacers that have a large molecular volume.

(iii) 4-Methylsulfonyl phenyl moiety at position 2 replaced the methyl group of indomethacin to develop COX-2 selectivity that can bind to the hydrophobic residue of COX-2 active site.

(iv) Omission of a carboxylic acid moiety at position 3 to overcome ulcerogenic potential.

(v) R 1, R 2 and R 3 alkyl substitution either electron-donating or withdrawing at position 5 to explore their electronic effect on anti-inammatory activity (Fig. 1) .

Herein, two series of indomethacin analogues were designed, synthesized and screened for their in vitro (COX1/2) inhibition and in vivo anti-inammatory activities. In addition, physicochemical parameters and molecular docking studies to explore molecular patterns on the COX-2 binding site will be discussed. Ulcer index and histopathological study for stomach samples are also included.

The synthesis of target compounds is depicted in Schemes 1 and 2. In the rst step, benzimidazole derivatives 7a-c were obtained from the reaction of 1-2-phenylenediamine derivatives 5a-c with 4-(methylthio) benzaldehyde (6) through oxidative condensation and cyclization according to a reported procedure 28 using either traditional heating or microwave irradiation. The use of microwave heating has the advantages of obtaining a good yield of up to 92%, less time consumed and DMF solvent used. Next, Compounds 7a-c were oxidized by oxone, wherein, -SCH 3 was oxidized to -SO 2 CH 3 , resulting in 8a-c with a yield of up to 95%. 29 Then, the alkylation of 8a-c with ethyl chloroacetate produces N-alkylated ester products 9a-c with a yield of up to 66%. The formation of 9a-c was conrmed by IR, 1 H NMR, and elemental analysis. The IR spectrum showed an ester (C] O) broad band at the range of 1730-1745 cm À1 . The 1 H NMR spectrum showed one triplet signal of aliphatic proton CH 3 CH 2 -, quartet signal of aliphatic proton CH 3 CH 2and a single signal of aliphatic proton -CH 2 CO in ranges of 1.12-1.17 d, 4.10-4.16 d and 5.33-5. 35 d, respectively. 30 Aer that, compounds 9a-c were reacted with hydrazine hydrate to produce moderate yields of hydrazides 10a-c. The IR spectra of compounds 10a-c showed amide (C]O), -NH 2 and -NH bands at approximately 1690, 3225 and 3330 cm À1 , respectively. The 1 H NMR spectra showed the disappearance of the signal of ethyl ester c protons and the appearance of exchangeable hydrazide -NH 2 and -NH protons at about d 4.43 and d 9.60, respectively. Finally, the condensation of the synthesized hydrazide derivatives 10a-c with different aldehydes or ketones resulted in benzylidene 11a-l and compounds 12a-f, respectively, in moderate yield. The IR spectra of compounds 11a-l and 12a-f showed the absence of hydrazide NH 2 bands. 29 1 H NMR spectra of 11a-l and 12a-f showed the respective proton patterns of the desired compounds, it also showed the presence of two geometrical isomers (E/Z) in different ratios (see ESI Table 1S †), which was conrmed not only by the presence of NCH 2 , N]CH, and CONH peaks as pairs of singlets but also conrmed by nuclear Overhauser effect spectroscopy (NOESY). Furthermore, both Z and E isomers, energies were minimized and the calculated total energy of compound 11b was 96.17 kcal mol À1 , which is lower if it were in E conguration (see ESI Table 2S †), we concluded that the E isomer is predominant in agreement with already reported data of this type of reaction. 31 2.2. Biology 2.2.1. In vitro cyclooxygenase (COX) inhibition assay. The synthesized compounds were in vitro screened to determine their ability to inhibit both bovine COX-1 and COX-2 isozymes. 32 The potency of the tested compounds was determined as the concentration causing 50% enzyme inhibition (IC 50 ). The COX-2 selectivity index (SI value) was calculated and specied as SI ¼ IC 50 (COX-1)/IC 50 (COX-2) and then compared to those of standards indomethacin, diclofenac sodium and celecoxib. As demonstrated in Table 1 , compounds 11b, 12b, and 12d exhibited very low selectivities towards COX-1 isozyme (IC 50 ¼ 13.41, 12.54, 13.21 mM), (respectively) compared to those of reference drugs indomethacin and celecoxib (IC 50 ¼ 0.04, 15.10 mM). On the other hand, COX-2 selectivity of compounds 11b, 12b, and 12d is high (IC 50 ¼ 0.10 mM) compared to reference drugs indomethacin and celecoxib (IC 50 ¼ 0.51, 0.05 mm) (respectively).

All tested compounds showed a higher selectivity index range (SI ¼ 23-134) than that of reference drugs indomethacin and diclofenac (SI ¼ 0.1, 5), (respectively). From tested compounds, the lowest selectivity against COX-2 was noticed for compounds 11l, 12a and 11h (SI ¼ 23, 32, 36), (respectively), but all are better than indomethacin.

2.2.2. Anti-inammatory activity. To determine anti-inammatory activities of the target compounds (11a-11d, 11f-11h, 11j-11i, 12a-12b, 12d and 12f) the carrageenaninduced rat paw edema model was used. 33 Results are shown in Table 2 . From the data obtained, most potent COX-2 inhibitor compounds 11b, 11c, 11j, 11k, 12b and 12d exhibit correlated anti-inammatory activity as they reduce inammation aer 6 hours by 95%, 93%, 93%, 95%, 95%, and 94.7%, (respectively). While compounds 11d, 11f and 11g, which exhibited moderate COX-2 inhibition activities (IC 50 ¼ 0.12, 0.13 and 0.13 mM, respectively) have acceptable inammation reduction properties (90%, 90% and 78% reduction of inammation aer 6 hours, (respectively) compared to the reference drug indomethacin 97% reduction of inammation aer 6 hours) and celecoxib (96% reduction of inammation aer 6 hours).

Further screening was performed for the most active anti-inammatory compounds 11b, 12d and 11k to determine the ulcerogenic effect (ulcer index), number of ulcers and preventive index. 34 Results and relative ulcerogenicity related to indomethacin and celecoxib are shown (see ESI Table S3 †) . Results showed that all tested compounds have a lower ulcerogenic effect than the reference drugs celecoxib and indomethacin. Compound 11b was safest one (Ulcer Index) (UI ¼ 0.83). Also compounds 12d and 11k showed lower ulcerogenic effect (Ulcer Index) (UI ¼ 1-4.5) (respectively) compared to that of non-selective COX-2, indomethacin (UI ¼ 13) and that of selective COX-2, celecoxib (UI ¼ 3.5).

2.2.4. Histo-pathological study. Examination of histopathological lesions was performed to evaluate the cariogenic effect of the most active compounds 11b, 12d and 11k on both glandular and non-glandular portions of rat's stomach, and to compare the severity of those lesions with those induced by celecoxib and indomethacin as reference drugs. 35 In the control negative group, a normal histological structure of the stomach could be found. The glandular stomach showed normal mucosa, submucosa and muscolosa. Moreover, a normal histological structure of the non-glandular stomach could be detected (see ESI Fig. S1A †) .

In the indomethacin group, severe lesions could be found in the form of degenerative changes and necrosis of glandular and non-glandular stomach. The glandular part exhibited ulcerative lesions and massive leucocytic inltration, congestion and edema in the submucosal layer. Hyalinosis of the muscular layer might possibly be associated with diffuse leucocytic inltration. The non-glandular stomach showed hyperkeratosis associated with multi-focal erosive and ulcerative lesions as well as hyperkeratosis (see ESI Fig. S1B †). In the celecoxib group, mild lesions could be found in the glandular stomach, mainly degenerative changes of the mucosal lining, and mild lymphocytic inltration in the submucosal layer. The non-glandular stomach portion exhibited minimal hyperkeratosis (see ESI Fig. S1C †) .

The administration of compounds 11b and 12d showed mild pathological lesions represented by degenerative changes of the mucosal lining and minimal submucosal lymphocytic inltration. The normal histological structure could be found in the nonglandular stomach histological structure (see ESI Fig. S1D †) .

The administration of compound 11k revealed the presence of mild to moderate lesions mainly in the form of degeneration in the lining epithelium associated with mild necrotic changes. Furthermore, mild to moderate submucosal congestion associated with mild leucocytic inltration was found, together with mild hyalinosis in the muscular layer. Moderate hyperkeratosis of the non-glandular stomach could be detected with the absence of any erosive or ulcerative lesions (see ESI Fig. S1E †) ( Table 3 ).

A molecular modeling study was conducted to explain the potential binding modes and the difference in the selectivity prole of the most active compounds toward COX subtypes. 36 a Data expressed as % inhibition and analyzed by one-way ANOVA (n ¼ 4), P < 0.05, all were signicant from control. 

a À/+ minimal, +/mild, ++/moderate, +++/severe. COX-2 crystalline structure data were obtained from a protein data bank (PDB ID: 1CX2). 49 Initial rescoring methodology (London dG) and the nal restoring methodology (GBVI/WSA dG) were used to score y poses of the targeted compounds and celecoxib. Triangle Matcher protocol was used for placement, and Rigid Receptor was used for post-placement renement. The investigated compounds showed binding modes as those of celecoxib with Arg120, which is the key amino acid of the active site. Celecoxib interacts with COX-2 active site through a sulfonamide moiety to form hydrogen bonds with Arg120 and through the Diazole ring to form a pi-H bond with Ser353. Furthermore, compounds 11b, 12d, 11k and 12b have extra binding interactions to receptor active sites, which may explain their superior activity compared to the activity of the rest of the compounds. The binding of the crystal structure of celecoxib with COX-2 receptor active site occurs by forming 2 hydrogen bonds with Ser353 and Arg120 amino acids through the diazole ring and sulfonyl moiety with 3.76, 2.84Å, respectively, and with affinity binding at the energy of À17.66 kcal mol À1 (Fig. 2 a and b for celecoxib). The docking process of the tested compounds shows adequate interaction with affinity range (energy score) (À12.13, À16.95 kcal mol À1 ) between the active pharmacophore and amino acid active site inside COX-2 receptors with a distance range 3.18-4.36Å from the main residue. These results complement those of celecoxib. The compound's higher selectivity is due to its higher binding affinity (see ESI new investigated drugs are known to be extremely difficult due to improper ADME (absorption, distribution, metabolism, and excretion) properties, as well as high costs. As a result, evaluating the pharmacokinetic properties of a new drug is a significant phase in drug development. 20, 38 In silico ADME screens can now be used to identify the most promising compounds and reduce late-stage drug attrition. 39 A compromise between pharmacodynamic and pharmacokinetic properties is required to achieve a favorable in vivo response. Additionally, oral bioavailability, brain penetration, the volume of distribution, and clearance predictions provide additional information about drug dosage and regimen. 40 Many parameters are investigated using virtual screening methods, such as human intestinal absorption HIA, partition coefficient (log p), drug solubility (S), topological polar surface area (TPSA), cell permeability, and drug-likeness score. An available oral drug is chosen in accordance with Lipinski's rule of ve if the molecular weight < 500, the number of hydrogen bond donors < 5, the number of hydrogen bond acceptors < 10, and Log P is <5. 41 The number of rotatable bonds is used to reect molecular exibility, which is important for oral bioavailability. It has also been proposed that the number of hydrogen bonding groups be replaced by topological polar surface area (TPSA) as a 3d descriptor in measuring percentage absorption (percent ABS) since it is inversely proportional to % ABS. % ABS ¼ 109-0.345 PSA.

Oral bioavailability should be high for compounds with TPSA of less than 140 A 2 and 10 or less rotatable bonds. 42 Herein, to predict the pharmacokinetic parameters of the most active compounds, we used the Molso, 43 SwissADME, 44 and pkCSM soware. 45 Results in (see ESI Table S6 †) show that most compounds obey Lipinski's rule, with MW ranging from 423.49 to 484.93 (<500), log P values ranging from 3.24 to 4.64 (<5), HBD ranging is 1 (<5), and HBA ranging from 5 to 6 (<10). As a result, they should have good oral absorption, but variations in bioactivity cannot be attributed to this property. Furthermore, the compounds had numbers of rotatable bonds ranging from 7 to 8 (<10) and TPSA values of 101.3 and 104.80 A 2 (140 A 2 ), respectively, with oral absorption percentage ranging from 70.69 to 73.87%, suggesting good permeability, absorption, and transport across biological membranes. In general, it is understood that an orally available molecule that meets both Lipinski's and Veber's rules is considered to have a combination of lipophilicity and hydrophilicity.

Compounds 11b, 11k and 12b, as illustrated in Table 4 satisfy both Lipinski's and Veber's criteria, indicating that they may be used as drug-like molecules. Molso soware was also used to evaluate the drug-likeness model score Table 4 .

The in silico analysis of the subsequent pharmacokinetic parameters was also carried out using pkCMS online soware, the predicted ADME parameters' outcomes are depicted (see ESI  Table S6 †). The ndings showed that all the tested molecules have signicant oral absorption values and nearly similar water solubility values. All the tested compounds are expected to have high cellular permeability, especially in intestinal cells (92.84-99.57%) the tested compounds were discovered to be substrates of P-glycoprotein, which is a member of the ATP-binding cassette transporter found primarily in epithelial cells. In addition, the observed lipophilicities have a negative correlation with the tested compound's water solubility potentials, but a positive correlation with human colon adenocarcinoma (CaCo-2) permeability.

Investigated compounds exhibited no correlation between the lipophilicity and drug permeability as measured by the previously reported (Caco-2) cell line assay. 46, 47 According to the drug distribution prediction, compounds 11k and 12d have the best blood-brain barrier (BBB) permeability in comparison to other tested compounds. Results show that the investigated compounds were relatively active, inhibiting CYP2C19, CYP2C9, and CYP3A4. The parameters related to metabolism and excretion did not show any signicant differences between the tested compounds, apart from compound 11k, which had a higher overall clearance than the others. In conclusion, the prediction of the toxicological properties of the tested compounds was applied by the pkCSM soware. Here, results show that all investigated compounds have no hepatotoxicity or skin sensitization. Regarding cardiotoxicity, all the tested compounds show no inhibition except for compounds 12b. Despite this, the toxicant of the tested compounds in T. pyriformis was high.

A novel series of potent COX-2 inhibitory benzimidazole derivatives was designed, synthesized and evaluated in vitro as (COX-1)/(COX-2) inhibitors and in vivo as anti-inammatory agents. All synthesized compounds showed higher selectivity than indomethacin. Compounds 11b, 11k, 12b and 12d showed the most robust activity with high COX-2 selectivity and inhibitory activity (SI ¼ 134, 123, 125, 132, respectively) (IC 50 ¼ 0.10 mM). The selected compounds showed a good gastric safety prole upon histopathological lesions examination from the rat stomach. Finally, in silico ADME predictions, physic-chemical properties and drug-likeness proles of the most active compounds were performed. As a result, it is possible to say that compounds 11b, 12b and 12d should be subjected to further studies.

Melting points were detected by the Tomas-Hoover capillary melting apparatus without any correction. All solvents, , and an equal amount of substituted o-phenylene diamine in addition to sodium meta-bisulte (1 g) dissolved in N,N-dimethyl formamide (DMF, 10 ml). The mixture was heated under reux with stirring at 110 C for 5-10 h. Aer completion of the reaction (monitored with TLC), the reaction mixture was poured into ice and the solid precipitate obtained was collected by ltration and washed several times with cold water (5 Â 20 ml). The crude product was recrystallized from ethanol and dried for further uses. 28 4.1.1.2 By microwave radiations. A mixture of 4-methylthio benzaldehyde (3.2 mmol, 0.5 g), and an equal amount of substituted o-phenylene diamine in addition to sodium meta-bisulte dissolved in N,N-dimethyl formamide (DMF, 10 ml). The mixture was heated by microwave radiation at 120 C and was stirred at 600 rpm. The completion of the reaction (monitored with TLC), the reaction mixture was poured into ice and the obtained solid precipitate was collected by ltration and washed several times with cold water (5 Â 20 ml). The crude product was recrystallized from ethanol and dried for further uses. 4.1.2. General procedure for the synthesis of (8a-c). Compounds (7a-c) (2 mmol) dissolved in 10 ml of methyl alcohol. Oxone (3.2 mmol, 1 g) dissolved in water then added and stirred under reux at 60-70 C. Oxidation was monitored by TLC then the reaction mixture was poured into cold water (50 ml). The product was extracted with EtOAc, and anhydrous Na 2 SO 4 was used to dry the organic layer to obtain the crude product, which was recrystallized from ethyl alcohol to obtain the targeted compounds 8a-c. 48 4.1. and anhydrous K 2 CO 3 (10 mmol, 1 g) was stirred cold for 2 h then ethyl chloroacetate (1.83 mmol, 0.256 ml) was added portion-wise. The reaction mixture was reuxed for 10 h then poured into ice and the product was obtained upon ltration. The products were conrmed by FTIR spectroscopy and 1 H NMR. 29 4.1.5. General procedure for the synthesis of (11a-i). A mixture of compounds 10a, 10b or 10c (1.45 mmol) and appropriate aromatic aldehyde (1.45 mmol) in ethyl alcohol (25 ml) was reuxed for 6 h in the presence of glacial acetic acid in a catalytic amount. The product was recrystallized from ethanol. 37 4.1.5.1 (E)-N 0 -Benzylidene-2-(2-(4-(methylsulfonyl) phenyl)-1H-benzo [d] imidazol-1-yl) acetohydrazide (11a). Pale brown; yield 60%; mp 150-152 C; IR: (KBr, cm À1 ) 3408 (NH), 1699 (C]O), 1614 (C]N), 1320-1158 (SO 2 ); 1 HNMR (DMSO-d 6 microtome was used to obtain 5m sections, which were stained by harris hematoxylin and Eosin as a general method of staining then outlined by Bancro and Stevens according to a previously reported method. 35 

'Molecular Operating Environment 2020.01' soware (MOE of Chemical Computing Group Inc., on a Core i7 2.2 GHz workstation) running on a Windows 10 PC which was used to carry out all docking studies and molecular modeling calculations. Xray crystal structure of COX-2 complexed with a selective inhibitor, celecoxib at 3Å resolution. The most active compounds as well as celecoxib were docked against COX-2 crystalline structure data obtained from the protein data bank (PDB ID: 1CX2). The MOE soware was used to conduct the docking analysis (chemical computing group soware, Canada 2020.01). Aer protonation, the lowest energy conformer of the tested compounds was docked to the active site. The docking conditions for all molecules were the same as for standard drugs. The 2D and 3D pictures are used to study the docking score and the binding interaction. 36 The docking phase of the tested compounds reveals that the active pharmacophore and amino acid active site interact well.

HMA-R and KRAA designed the idea, and the protocol of the whole study. MASB synthesized the compounds and wrote the experimental parts. MASB, HMA-R and EKAA interpreted the spectral data and modeling study. EE carried out a histopathological study. All authors read and approved the nal manuscript.

There are no conicts of interest to declare.

-(methylsulfonyl) phenyl)-1H-benzo[d]imidazol-1-yl) acetohydrazide (11b)

31 (s, 3H, SO 2 CH 3 ), 5.62 (s, 2H, CH 2 )

d, 2H, J ¼ 8.00 Hz, phenyl H-2, H-6

-(methylsulfonyl) phenyl)-1H-benzo[d]imidazol-1-yl) acetohydrazide (11c)

08 (s, 1H CH]N), 11.6 (s, 1H, NH, D 2 O exchangeable), 13 C DEPT-Q NMR (100 MHz DMSO-d 6 ): d 43.57 (CH 2 aliphatic

-(methylsulfonyl) phenyl)-1H-benzo[d]imidazol-1-yl) acetohydrazide (11d)

H-2, H-3, H-5, H-6) 8.04-8.06 (d, 2H, J ¼ 8.00 Hz, phenyl H-2

Pale brown solid; yield 45%; mp 149-151 C; IR: (KBr, cm À1 ) 3404 (NH), 1695 (C]O), 1611 (C]N)

SO 2 ); 1 HNMR (DMSO-d 6 , 400 MHz, d ppm): 3.31 (s, 3H, SO 2 CH 3 ), 5.63 (s, 2H

Yellow solid; yield 41%; mp 162-164 C; IR: (KBr, cm À1 ) 3408 (NH

MHz DMSO-d 6 ): d 43.74 (CH 2 aliphatic)

methylsulfonyl) phenyl)-1H-benzo[d]imidazol-1-yl) acetohydrazide (11h

81 (s, 1H, NH, D 2 O exchangeable), 13 C NMR (100 MHz DMSO-d 6 ): d 43.33 (CH 2 aliphatic)

methylsulfonyl) phenyl)-1H-benzo[d]imidazol-1-yl) acetohydrazide (11i

29 (s, 3H, SO 2 CH 3 ), 5.67 (s, 2H, CH 2 ), 7.14-7.16 (d, 1H, J ¼ 8.00 Hz benzimidazole

80 (s, 1H, NH, D 2 O exchangeable)

SO 2 ); 1 HNMR (DMSO-d 6 , 400 MHz, d ppm): 2.26 (s, 3H, CH 3 ), 3.30 (s, 3H, SO 2 CH 3 ), 5.58 (s, 2H, CH 2 )

-methyl-2-(4-(methylsulfonyl) phenyl)-1H-benzo[d]imidazol-1-yl) acetohydrazide (11k)

H-6), 7.49 (s, 1H, benzimidazole, H-4), 7.73-7.75 (d, 1H, J ¼ 8.00 Hz, benzimidazole

CH 2 aliphatic)

SO 2 ); 1 HNMR (DMSO-d 6 , 400 MHz, d ppm): 2.44 (s, 3H, CH 3 ), 3.26 (s, 3H, SO 2 CH 3 ), 5.56 (s, 2H, CH 2

A mixture of compounds 10a, 10b or 10c (1.45 mmol) and appropriate aromatic ketones (1.45 mmol) in ethyl alcohol (25 product recrystallized from ethanol

t, 2H, benzimidazole H-5, H-6

Dark brown solid; yield 62%; mp 167-169 C; IR: (KBr, cm À1 ) 3407 (NH

(d, 1H, J ¼ 8.00 Hz, phenyl hydrazone, H-6), 7.86-7.78 (d, 2H, J ¼ 8.00 Hz, phenyl hydrazone

Buff solid; yield58%; mp 168-170 C; IR: (KBr, cm À1 ) 3402 (NH

29 (s, 3H, SO 2 CH 3 ), 5.57 (s, 2H

CH 2 aliphatic)

400 MHz, d ppm): 2.25 (s, 3H, CH 3 ), 3.25 (s, 3H, SO 2 CH 3 ), 5.69 (s, 2H, CH 2 ), 7.31-7.33 (d, 1H, J ¼ 8.00 Hz, benzimidazole, H-6), 7.46-7.48 (d, 2H, J ¼ 8.00 Hz, benzoimidazole

Off white; yield 56%; mp 173-175 C; IR: (KBr, cm À1 ) 3409 (NH

89 (s, 3H, CH 3 ), 3.30 (s, 3H, SO 2 CH 3 ), 6.16 (s, 2H

d, 2H, J ¼ 8.00 Hz, phenyl, H-2, H-6), 8.43-8.45 (d, 2H, J ¼ 8.00 Hz, phenyl, H-3H-, H-5

SO 2 ); 1 HNMR (DMSO-d 6 , 400 MHz, d ppm): 2.26 (s, 3H, CH 3 ), 2.47 (s, 3H, CH 3 ), 3.28 (s, 3H, SO 2 CH 3 ), 5.64 (s, 2H, CH 2 )

Synthesis and Biological Evaluation of Novel 1, 2, 5-Substituted Benzimidazole Derivatives as Gastroprotective Anti-inammatory and Analgesic Agents

Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs?

Synthesis and biological evaluation of 2-(4-methylsulfonyl phenyl) indole derivatives: multi-target compounds with dual antimicrobial and anti-inammatory activities

Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview

3-Methyl-2-phenyl-1-substituted-indole derivatives as indomethacin analogs: design, synthesis and biological evaluation as potential anti-inammatory and analgesic agents

Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs as potential selective cyclooxygenase-2 (COX-2) inhibitors

N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation

Cyclooxygenase-2: a therapeutic target

Synthesis and evaluation of mutual prodrugs of ibuprofen with menthol, thymol and eugenol

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinammatory and nonulcerogenic

Novel 4-methylsulfonylphenyl derivatives as NSAIDS with preferential COX-2 inhibition

Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1, 5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors

Castrejón-Flores and I. I. Padilla-Martínez, Anti-inammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1, 2-diphenylbenzimidazole pharmacophore

Cyclooxygenase-2 inhibitors. 1, 5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/ cyclooxygenase-1 selectivity

Synthesis and antiinammatory and analgesic properties of 2-amino-1H-benzimidazole and 1, 2-dihydro-2-iminocycloheptimidazole derivatives

Antiproliferative effects of 6-anilino-5-chloro-1H-benzo [d] imidazole-4, 7-dione in vascular smooth muscle cells

Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity relationship of oncodazole analogs

Synthesis and antimicrobial activity of some novel phenyl and benzimidazole substituted benzyl ethers

Antimicrobial activities of some tetrahydronaphthalene-benzimidazole derivatives

Abou El-Ella, Design, synthesis, mechanistic studies and in silico ADME predictions of benzimidazole derivatives as novel antifungal agents

Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones

Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists

Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids

Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents

Synthesis and In-vivo Evaluation of Carbonylamide Linkage Based New Benzimidazole Derivatives

Synthesis of some new benzimidazolecarboxamides and evaluation of their antimicrobial activity

The proton-pump inhibitors: similarities and differences

Synthesis and antioxidant properties of novel N-methyl-1, 3, 4-thiadiazol-2-amine and 4-methyl-2H-1, 2, 4-triazole-3 (4H)-thione derivatives of benzimidazole class

Synthesis and antimicrobial activities of some novel benzimidazole and benzotriazole derivatives containing blactam moiety

Synthesis, physicochemical properties and antimicrobial activity of some new benzimidazole derivatives

First synthesis and isolation of the E-and Z-isomers of some new Schiff bases. Reactions of 6-azido-5-formyl-2-pyridone with aromatic amines

Pro-inammatory enzymes, cyclooxygenase 1, cyclooxygenase 2, and 5-lipooxygenase, inhibited by stabilized rice bran extracts

3-Methyl-2-phenyl-1-substituted-indole derivatives as indomethacin analogs: design, synthesis and biological evaluation as potential anti-inammatory and analgesic agents

Effect of prostaglandin E1 on gastric secretion and ulcer formation in the rat

Theory and Practice of Histological Techniques

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inammatory agents

Conventional and microwave assisted synthesis of 2-oxo-4-substituted arylazetidine derivatives of benzotriazole: A new class of biological compounds

Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors

admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties

ADMET in silico modelling: towards prediction paradise

Environmentally benign synthesis, molecular properties prediction and anti-inammatory activity of novel isoxazolo [5, 4-d] isoxazol-3-yl-aryl-methanones via vinylogous Henry nitroaldol adducts as synthons

Molecular properties that inuence the oral bioavailability of drug candidates

Quinazoline-Schiff base conjugates: in silico study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins

Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells

Synthesis and Antifungal Activity of Substituted 2-Aryl Benzimidazoles Derivatives

4.2.1. In vitro cyclooxygenase (COX) inhibition assay. An enzyme immune assay (EIA) kit (Cayman Chemical, Ann Arbor, MI, USA) was used to determine the ability of the targeted compounds shown in Table 1 to inhibit both ovine COX-1 and COX-2 following a previously reported method. 32 4.2.2. In vivo anti-inammatory (AI) assay. Carrageenan induced paw edema model was used in accordance with Nahda University guidelines and was approved by the ethical committee of Nahda University, Beni-Suef, Egypt (approval no. NUB-024-21). The tested compounds 11a-11d, 11f-11h, 11j-11l, 12a, 12b and 12c as well as celecoxib and indomethacin as reference drugs were evaluated for their in vivo anti-inammatory activities. The rst group (negative control) received 5% DMSO aqueous solution (v/v), the second group received celecoxib as a reference drug (10 mg kg À1 ; po), the third group received indomethacin as a reference drug (10 mg kg À1 ; po) and the other groups received tested compounds (10 mg kg À1 ; po) in form of 5% DMSO aqueous solution. The induction of inammation started 30 minutes aer receiving the treatment. Carrageenan (0.02 ml of 1%) was injected sub-plantar to induce paw edema. Paw thickness was measured 1 hour, 3 hours, and 6 hours aer the carrageenan injection according to the following equation, edema inhibition (%) ¼ (T c À T t /T c ) Â 100 where T t represents the mean increase in paw thickness in rats treated with the tested compound; T c represents the mean increase in paw thickness in rats of the control group using a previously described method. 32 Percent of inhibition for the most active drugs in addition to celecoxib and indomethacin is listed in Table 2 .4.2.3. Ulcerogenic liability. Ulcerogenic effect (ulcer index), number of ulcers, and preventive index were studied for the most potent anti-inammatory drugs 11b, 12d and 11k compared to those for indomethacin and celecoxib. Aer 4 h of drug administration, rats were sacriced. Findings have shown satisfactory results of the tested drug against the reference drugs celecoxib and indomethacin following a previously mentioned method. 34 4.2.4. Histo-pathological study for in vivo ulcer liability. 10% buffered formalin was used to ush glandular and nonglandular collected stomach samples for 72 h. Collected samples encountered preparing processes such as trimming, dehydration by different concentrations of alcohol, clearing in xylene and blocking out into paraplast tissue. Rotatory